FUROSEMIDE

The medication should be administered in the morning to avoid nocturnal diuresis.

Adults (more than 18 years of age):

The usual initial daily dose is 40mg. This may be adjusted until an effective dose is achieved. Elderly In the elderly, furosemide is generally eliminated more slowly. Dosage should be titrated until the required response is achieved.

4). This product should not be mixed with food or beverages before use. Method of administration For oral administration only The syringe adaptor should be placed in the neck of the bottle and the required dose should be drawn from the container into the graduated oral syringe provided.

The open end of the syringe should be placed in the mouth of the patient, and the piston slowly depressed to release the contents.

g. in nephritic syndrome) and/or when intravenous furosemide has been given too rapidly) Eye disorders Visual disturbance Gastrointestinal disorders Dry mouth, thirst, nausea, bowel motility disturbances, vomiting, diarrhea, constipation Acute Pancreatitis General disorders and administration site conditions Fatigue Malaise, Fever Hepato-biliary In isolated cases disorders intrahepatic cholestasis, an increase in liver transaminases or acute pancreatitis may develop.

4) Hypocalcemia, hypomagnesemi a, metabolic alkalosis, Bartter syndrome (when misuse and/or prolonged furosemide use) Musculoskeleta l and connective tissue disorders Muscle cramps, muscle weakness Nervous system disorders Paraesthesia, hyperosmolar coma Dizziness, fainting and loss of consciousness (caused by symptomatic hypotension) Psychiatric disorders Psychiatic disorders NOC Renal and urinary disorders Serum creatinine and urea levels can be temporarily elevated during treatment with furosemide Interstitial nephritis, acute renal failure Increased urine production, urinary incontinence, can be caused or symptoms can be exacerbated in patients with urinary tract obstruction.

g. g. with shock) Premature infants In general, if furosemide is administered to premature infants during the first weeks of life, it may increase the risk of persistence of patent ductus arteriosus. Risk of nephrocalcinosis/nephroliathisis.

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

This product should not be given to children because its ethanol content may affect their CNS. Caution is required in patients liable to electrolyte deficiency. Regular monitoring of serum sodium, potassium and creatinine is generally recommended during furosemide therapy; particularly close monitoring is required in patients at high risk of developing electrolyte imbalances or in case of significant additional fluid loss.

Hypovolaemia or dehydration as well as any significant electrolyte and acid-base disturbances must be corrected. This may require temporary discontinuation of furosemide. Where indicated, steps should be taken to correct hypotension or hypovolaemia before commencing therapy.

Urinary output must be secured. Patients with partial obstructions of urinary outflow for example patients with prostatic hypertrophy or impairment of micturition have an increased risk of developing acute urinary retention and require careful monitoring.

g. associated with nephrotic syndrome (the effect of furosemide may be weakened and its ototoxicity potentiated). Symptomatic hypotension leading to dizziness, fainting or loss of consciousness can occur in patients treated with furosemide, particularly in the elderly, patients on other medications which can cause hypotension and patients with other medical conditions that are risks for hypotension.

Cautious dose titration is required • Patients that might manifest latent diabetes • Diabetic patients who might show increased insulin requirements The use of some diuretics is considered to be unsafe in acute porphyria therefore caution should be exercised.

1%; mean age 80 years, range 67-90 years). Concomitant use of risperidone with other diuretics (mainly thiazide diuretics used in low dose) was not associated with similar findings. No pathophysiological mechanism has been identified to explain this finding, and no consistent pattern for cause of death observed.

Hypovolaemia or dehydration. Anuria. Renal failure with anuria not responding to furosemide, or as a result of poisoning by nephrotoxic or hepatotoxic agents, or associated with hepatic coma. Severe hypokalaemia and severe hyponatraemia.

Pre- comatose and comatose states associated with hepatic encephalopathy. Breast feeding. Contra-indicated in hypersensitivity to Furosemide, sulphonamides or any of the excipients listed. Patients allergic to sulphonamides may show cross-sensitivity to furosemide.